Certificate under Regulation 74(5) for Quater and half year ended on 30th September, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Eiko Lifesciences has submitted a routine SEBI compliance certificate to BSE for the quarter ended 30 September 2025. The certificate was issued by the company's Registrar and Share Transfer Agent, Bigshare Services Pvt. Ltd. It confirms that no dematerialisation requests (converting physical shares into electronic/demat form) were received from shareholders during 1 July 2025 to 30 September 2025. The filing was signed by Chintan Doshi, Company Secretary and Compliance Officer, on 11 October 2025. This is a standard quarterly regulatory submission required under SEBI's depository rules, with no new business or financial information disclosed.
This is a routine compliance filing with no impact on the company's operations, financials, or stock price. Shareholders do not need to take any action — the certificate simply confirms that no shareholder asked to convert physical shares into demat form during the quarter.